NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease

Jun Yin, Fanpeng Zhao, Jeremy E. Chojnacki, Jacob Fulp, William L. Klein, Shijun Zhang, Xiongwei Zhu*

*Corresponding author for this work

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

The activation of the NLRP3 inflammasome signaling pathway plays an important role in the neuroinflammation in Alzheimer’s disease (AD). In this study, we investigated the effects of JC-124, a rationally designed NLRP3 inflammasome inhibitor, on AD-related deficits in CRND8 APP transgenic mice (TgCRND8). We first demonstrated increased formation and activation of NLRP3 inflammasome in TgCRND8 mice compared to non-transgenic littermate controls, which was inhibited by the treatment with JC-124. Importantly, JC-124 treatment led to decreased levels of Aβ deposition and decreased levels of soluble and insoluble Aβ1–42 in the brain of CRND8 mice which was accompanied by reduced β-cleavage of APP, reduced activation of microglia but enhanced astrocytosis. Oxidative stress was decreased and synaptophysin was increased in the CRND8 mice after JC-124 treatment, demonstrating a neuroprotective effect. Overall, these data demonstrated beneficial effects of JC-124 as a specific NLRP3 inflammasome inhibitor in AD mouse model and supported the further development of NLRP3 inflammasome inhibitors as a viable option for AD therapeutics.

Original languageEnglish (US)
Pages (from-to)1977-1987
Number of pages11
JournalMolecular Neurobiology
Volume55
Issue number3
DOIs
StatePublished - Mar 1 2018

    Fingerprint

Keywords

  • Alzheimer’s disease
  • Amyloid-beta
  • Inflammasome
  • NLRP3
  • Neuroinflammation

ASJC Scopus subject areas

  • Neurology
  • Cellular and Molecular Neuroscience

Cite this